Semaglutide common uses, half-life, side effects and more

Semaglutide is a long-acting GLP-1 receptor agonist taken once weekly by subcutaneous injection or once daily as a tablet. It is approved under separate brand names for different jobs. Ozempic treats type 2 diabetes and lowers heart and kidney risk in people who already have that disease. Wegovy reduces body weight alongside diet and exercise. It also lowers cardiovascular risk in people who already have heart disease. Rybelsus is a daily tablet for diabetes that carries an absorption enhancer so the peptide survives the stomach. The tablet and the injection are not interchangeable by milligram amount. Powder sold by research vendors and counterfeit or compounded vials are not the approved product and are not held to the same standard.

• Long-term weight reduction in obesity or overweight with a weight-related condition
• Blood sugar control in adults with type 2 diabetes
• Lowering heart attack and stroke risk with established cardiovascular disease
• Slowing kidney disease progression in type 2 diabetes
• Reducing liver scarring in noncirrhotic MASH with moderate to advanced fibrosis
• Weight loss bought outside approved channels as research powder

Once weekly by injection or once daily as a tablet

The subcutaneous injection for weight management starts at 0.25 mg once weekly and steps up about every 4 weeks through 0.5 mg, 1 mg, and 1.7 mg to a 2.4 mg weekly target. The diabetes injection climbs from 0.25 mg to 0.5 mg to 1 mg weekly and tops out at 2 mg. Gray-market users reconstitute research powder from 5 mg or 10 mg vials and copy the same slow climb. Many settle well below the 2.4 mg ceiling. The daily diabetes tablet is taken on an empty stomach and steps from 3 mg to 7 mg to 14 mg. A 7.2 mg weekly injection and a 25 mg daily tablet are approved higher-dose options for weight management.

• Reconstituting a 5 mg or 10 mg vial to 2.5 mg per mL makes a 0.25 mg starting dose land on 10 units of a U-100 insulin syringe
• Swallow the tablet whole in the morning with a small sip of plain water and wait at least 30 minutes before food, drink, or other pills
• The injection can be taken any time of day with or without food
• Never convert a dose between the tablet and the injection or between brands by milligram amount
• A weekly injection can be taken up to 5 days late before it should be skipped to the next scheduled day

About 1 week (roughly 168 hours) in humans. This is a true terminal half-life and supports once-weekly injection. The oral tablet is the same molecule and is taken daily only because so little of it is absorbed.

Unused pens stay refrigerated between 2 and 8 degrees Celsius. An Ozempic pen in use lasts up to 56 days at room temperature up to 30 degrees. A single-dose Wegovy pen lasts up to 28 days out of the fridge. Do not freeze any semaglutide product and keep it out of light. Tablets are stored at room temperature in the original bottle away from moisture.

• Nausea is the most common effect and reached 44 percent at the 2.4 mg dose against 16 percent on placebo
• Diarrhea, vomiting, and constipation are common and cluster during the dose climb
• Decreased appetite, abdominal pain, headache, and fatigue are frequent
• Hair shedding can happen during rapid weight loss and eases afterward
• Gallstones, pancreatitis, and kidney injury from dehydration are uncommon but serious
• Low blood sugar becomes likely when the injection is combined with insulin or a sulfonylurea

Semaglutide activates the GLP-1 receptor and acts at that receptor alone. This raises insulin release only when blood sugar is high and lowers glucagon on the same terms. It slows stomach emptying and reduces appetite through satiety pathways in the brain. Food intake falls in human studies while the exact brain circuit is mapped mainly in animals. The molecule is a modified copy of human GLP-1. A change at position 8 blocks the enzyme that would otherwise break it down within minutes. A C18 fatty diacid chain binds it to albumin in the blood and is the main reason its action lasts about a week. The oral tablet adds an absorption enhancer that shields the peptide in the stomach and helps it cross the lining. Absolute oral absorption still stays near 1 percent.

The human evidence base is very large and spans blood sugar, weight, heart, and kidney outcomes. STEP 1 gave the 2.4 mg weekly injection for 68 weeks and produced 14.9 percent mean weight loss against 2.4 percent on placebo. SELECT enrolled 17,604 adults with obesity and heart disease but no diabetes and cut major cardiovascular events by 20 percent. SUSTAIN 6 found fewer cardiovascular events in high-risk type 2 diabetes and also recorded more diabetic retinopathy complications. FLOW showed slower kidney disease progression in diabetic chronic kidney disease. The oral tablet carries its own cardiovascular outcome trials through the PIONEER and SOUL programs. Longer follow-up shows that lost weight returns after treatment stops. Evidence for compounded, salt-form, counterfeit, or research-labeled semaglutide is not the same as evidence for the approved products.

• A boxed warning covers thyroid C-cell tumors seen in rodents and rules out use with a personal or family history of medullary thyroid carcinoma or MEN 2
• Gray-market powder has no verified strength and a chart written for one vial size and water volume gives the wrong syringe units for another
• Severe or persistent abdominal pain can signal pancreatitis or gallbladder disease and needs prompt medical care
• Delayed stomach emptying has left food in the stomach before anesthesia so a procedure team needs to know about current use
• Semaglutide should stop at least 2 months before a planned pregnancy and weight-management use should stop once pregnancy is recognized
• Stacking semaglutide with another GLP-1 drug adds side effects without added benefit and should be avoided